The estimated Net Worth of Jay Strum is at least $1.52 Million dollars as of 2 January 2019. Jay Strum owns over 79,818 units of G1 Therapeutics Inc stock worth over $921,460 and over the last 7 years he sold GTHX stock worth over $596,000. In addition, he makes $0 as Chief Scientific Officer at G1 Therapeutics Inc.
Sign up
Jay Strum GTHX stock SEC Form 4 insiders trading
Jay has made over 3 trades of the G1 Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 79,818 units of GTHX stock worth $27,936 on 2 January 2019.
The largest trade he's ever made was exercising 79,818 units of G1 Therapeutics Inc stock on 2 January 2019 worth over $27,936. On average, Jay trades about 18,134 units every 25 days since 2017. As of 2 January 2019 he still owns at least 129,237 units of G1 Therapeutics Inc stock.
You can see the complete history of Jay Strum stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jay Strum biography
Dr. Jay C. Strum Ph.D. is the Chief Scientific Officer of G1 Therapeutics Inc. Dr. Strum has served as our Chief Scientific Officer since 2009, and in addition to this role, served as our President and a member of our board of directors from 2011 until 2014. Prior to joining us, Dr. Strum served as a scientist, manager and then Director of the Genomics Division at GlaxoSmithKline plc, or GSK, a British pharmaceutical company, from May 1995 to February 2009, where he developed drugs in multiple therapeutic areas and target classes with a focus on kinases. In his role as a manager at GSK, Dr. Strum served as a program leader of interdisciplinary research and development teams in early drug discovery in metabolic diseases and oncology, and he contributed to the discovery of numerous drug candidates and the development of three approved drugs, including TYKERB. As the Director of the Genomics Division at GSK, he led the creation and operation of an international department responsible for supporting genomics research in all therapeutic areas within GSK. Dr. Strum is the author of more than 40 scientific publications and co-inventor of all intellectual property owned or co-owned by the Company that covers trilaciclib or G1T38 or their method of use, which consists of 11 patent families with five issued U.S. patents. Dr. Strum is also the co-inventor of another six patent families and six issued patents that cover additional compounds of interest. In total, Dr. Strum is a co-inventor of more than 75 applications that have entered the national phase of prosecution in countries outside the United States. Dr. Strum received his B.S. and B.A. from Western Carolina University and his Ph.D. in biochemistry from Wake Forest University.
How old is Jay Strum?
Jay Strum is 54, he's been the Chief Scientific Officer of G1 Therapeutics Inc since 2016. There are 17 older and 9 younger executives at G1 Therapeutics Inc. The oldest executive at G1 Therapeutics Inc is Fredric Eshelman, 72, who is the Independent Director.
Insiders trading at G1 Therapeutics Inc
Over the last 8 years, insiders at G1 Therapeutics Inc have traded over $53,962,020 worth of G1 Therapeutics Inc stock and bought 1,541,753 units worth $24,259,954 . The most active insiders traders include Capital Management, L.P.Ra ..., Fredric N Eshelman, and Glenn P Muir. On average, G1 Therapeutics Inc executives and independent directors trade stock every 17 days with the average trade being worth of $198,620. The most recent stock trade was executed by Andrew Perry on 5 July 2024, trading 1,337 units of GTHX stock currently worth $3,356.
What does G1 Therapeutics Inc do?
g1 therapeutics is a clinical-stage company developing small-molecule therapies to address significant unmet needs in oncology. the company is leveraging its proprietary kinase drug discovery platform to advance a pipeline of best-in-class compounds and first-in-class drug candidates.
What does G1 Therapeutics Inc's logo look like?
Complete history of Jay Strum stock trades at G1 Therapeutics Inc
G1 Therapeutics Inc executives and stock owners
G1 Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Mark Avagliano,
Chief Business Officer -
James Hanson,
General Counsel, Secretary -
Mark Velleca,
President, Chief Executive Officer, Director -
Terry Murdock,
Chief Operating Officer -
Garry Nicholson,
Independent Chairman of the Board -
Jennifer Moses,
Chief Financial Officer -
Rajesh Malik,
Chief Medical Officer, Senior Vice President - Research and Development -
Dr. Mark A. Velleca M.D., Ph.D.,
Sr. Advisor & Director -
Mark Avagliano,
Chief Bus. Officer -
Dr. Rajesh K. Malik Ch.B., M.B., M.D.,
Chief Medical Officer and Sr. VP of R&D -
Dr. Rajesh K. Malik,
Chief Medical Officer and Sr. VP of R&D -
Andrew Perry,
Chief Commercial Officer -
Jennifer K. Moses CPA,
Chief Financial Officer -
Jennifer K. Moses,
Chief Financial Officer -
Seth Rudnick,
Independent Director -
Glenn Muir,
Independent Director -
Cynthia Schwalm,
Independent Director -
Fredric Eshelman,
Independent Director -
Willie Deese,
Independent Director -
Andrew Witty,
Independent Director -
John Bailey,
Independent Director -
Soma Gupta,
Chief Commercial Officer -
Jay Strum,
Chief Scientific Officer -
Terry L. Murdock,
Chief Operating Officer -
Blake Jensen,
VP of Quality & Compliance -
William C. Roberts,
VP of Investor Relations & Corp. Communications -
Dr. Jay C. Strum,
Chief Scientific Officer -
Alexander D. Smith M.S.,
VP of Technical Operations -
John E. Bailey Jr.,
CEO, Pres & Director -
Clay Hatteras Venture Advis...,
-
Capital Management, L.P.Ra ...,
-
Christy L Shaffer,
Director -
Ventures, Inc. Med Immune,
10% owner -
Ventures, Llc Eshelman,
10% owner -
Clay Hatteras Venture Advis...,
-
Barclay A Phillips,
SVP & Chief Financial Officer -
Monica R. Thomas,
Chief Legal & People Officer -
Jacks Lee,
-
John Demaree,
Chief Commercial Officer -
Alicia Secor,
-
Cynthia Louise Flowers,
-
Andrew Perry,
Chief Commercial Officer -
Norman Sharpless,
-
John W. V Umstead,
Chief Financial Officer